Specifix Dx

Antibiotics have revolutionized the way we treat infections. But in 2019 alone, antibacterial resistance was the direct cause of 1.27 million deaths around the world, 216,000 of which were associated with the inappropriate treatment of urinary tract infections. Unfortunately, unreliable urine tests are the leading cause for inaccurate diagnosis and treatment. To address this challenge, Specifix Dx introduces UroStix, a rapid test with a novel biomarker which will increase the accuracy of detection by over one third. To reflect this impact on a global scale, UroStix could protect 11 million people from unnecessary exposure to antibiotics every year.

With greater specificity, false positives can be avoided and users can trust their results. We believe that UroStix has the potential to not only help people with spinal cord injury, but those who acquire neurogenic bladder for other reasons, including neurodegenerative disorders and advanced age.